Mark Roithmayr Appointed As Our First CEO


Our Board of Governors has appointed Mark Roithmayr as Chief Executive Officer. Mr. Roithmayr is the first person to hold the CEO position at the ADDF.

$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments


We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.  

Donald Newhouse Honored for His Efforts to End a Rare Form of Dementia


On Monday, November 14, Donald Newhouse received The Charles Evans Award from the Alzheimer’s Drug Discovery Foundation (ADDF) at our Seventh Annual Fall Symposium & Luncheon "Hope on the Horizon" at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.

$1.5 Million in New Grant Funding for Promising Treatments


The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million. 

Alzheimer’s Drug Discovery Foundation Launches Expanded Brain Health and Dementia Prevention Website


The streamlined site separates fact from fiction and empowers people to make smarter choices for their brain health.

New Clinical Trial Will Test Cancer Drug as Alzheimer’s Treatment


Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF, says: “The ADDF is proud to support a clinical trial that holds such promise for Alzheimer’s patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer’s.”

Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain


Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death

Vivreon Biosciences Awarded Grant to Advance Drug Program Targeting Neuroinflammation


Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.

$1.7 Million Grant Supports Promising Drug That Targets Cannabinoid Receptor


With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.

Dr. D. Martin Watterson Wins Second Melvin R. Goodes Prize


Dr. Watterson Has Identified a Number of New Classes of Central Nervous System Drugs